Carlos Marugán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carlos Marugán has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso de Dios
Eli Lilly and Company, Indianapolis, Indiana
22 shared publications - Andrew Capen
Eli Lilly and Company, Indianapolis, Indiana
22 shared publications - Anke Klippel
Eli Lilly and Company, New York City, New York
22 shared publications - Baohui Zhao
Eli Lilly and Company, Indianapolis, Indiana
22 shared publications - Brian Mattioni
Eli Lilly and Company, Indianapolis, Indiana
22 shared publications - Cecilia Mur
Eli Lilly and Company, Alcobendas, Spain
22 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Imlunestrant, elacestrant, and fulvestrant mediated ER degradation, PGR gene inhibition and cell proliferation inhibition in T-47D parental and T-47D ESR1-Y537N cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Imlunestrant, elacestrant, and fulvestrant mediated ER degradation, PGR gene inhibition and cell proliferation inhibition in T-47D parental and T-47D ESR1-Y537N cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Imlunestrant PK/PD and uterotrophic activity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Imlunestrant PK/PD and uterotrophic activity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
In vivo single agent imlunestrant efficacy in ESR1-mutant and wild type xenograft and PDX breast cancer models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
In vivo single agent imlunestrant efficacy in ESR1-mutant and wild type xenograft and PDX breast cancer models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Biochemical and in vitro characterization of imlunestrant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Biochemical and in vitro characterization of imlunestrant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
In vivo imlunestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in CDX breast cancer models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
In vivo imlunestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in CDX breast cancer models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical analysis of imlunestrant and fulvestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in ESR1-wild type and mutant xenograft and PDX breast cancer models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical analysis of imlunestrant and fulvestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in ESR1-wild type and mutant xenograft and PDX breast cancer models
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical analysis of imlunestrant and fulvestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in ESR1-wild type and mutant xenograft and PDX breast cancer models
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical analysis of imlunestrant and fulvestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in ESR1-wild type and mutant xenograft and PDX breast cancer models
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical survival analysis and body weight change in MCF-7 intracranial model treated with imlunestrant or other SERDs.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical analysis of imlunestrant and fulvestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in ESR1-wild type and mutant xenograft and PDX breast cancer models
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer
Statistical analysis of imlunestrant and fulvestrant efficacy alone and in combination with abemaciclib, alpelisib, and everolimus in ESR1-wild type and mutant xenograft and PDX breast cancer models